ProQR Therapeutics N.V.
ProQR Therapeutics N.V. (NASDAQ: PRQR) is trading at $1.65, about ₹158 at today's USD/INR rate, as of 25 Sep 2026, 4:00 PM ET, down 3.51% today. Indian residents can buy ProQR Therapeutics from India on Paasa under the RBI's Liberalised Remittance Scheme.
Quote
Today's low
$1.63
Today's high
$1.72
52 week low
$1.33
52 week high
$3.10
PRQR opened at $1.72, closed previously at $1.71, and has traded between $1.33 and $3.10 over the past 52 weeks.
About
ProQR Therapeutics N.V. operates as a biopharmaceutical enterprise dedicated to discovering and developing RNA-based therapies designed to address genetic disorders. The company's pipeline includes two primary drug candidates in advanced clinical stages: Sepofarsen is currently in a Phase II/III clinical trial, known as the ILLUMINATE trial, targeting Leber Congenital Amaurosis 10 (LCA10). Ultevursen is also undergoing Phase II/III evaluation for the treatment of USH2A-mediated retinitis pigmentosa and Usher syndrome. Beyond its clinical programs, ProQR is actively developing its proprietary Axiomer RNA base-editing platform technology. Strategic collaborations are central to ProQR's strategy, evidenced by its licensing agreements with institutions such as Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center. Furthermore, a significant license and research partnership exists with Eli Lilly and Company, focused on the discovery, advancement, and commercialization of novel medicines for genetic conditions impacting the liver and nervous system. Established in 2012, ProQR Therapeutics N.V. maintains its corporate headquarters in Leiden, the Netherlands.
Key statistics
Avg. volume
954.11K
Market cap
$173.76M
P/E Ratio
-3.66
Price-to-sales ratio
8.21
Enterprise value
€48.64M
Free cash flow yield
-32.97%
Debt-to-equity ratio
0.17
Return on equity
-68.44%
ROIC
-41.91%
Beta
0.03
Dividend yield
0.00%
Last dividend
$0.00
Financial overview
Revenue
€15.28M
Earnings per share
-€0.38
Free cash flow
-€53.81M
Net profit margin
-228.29%
Gross margin
92.33%
EBITDA
-€37.04M
Revenue growth
-19.18%
Similar securities
This is not an investment recommendation
How to buy ProQR Therapeutics from India
Indian residents can buy ProQR Therapeutics shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.
Open a Paasa account
Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Add funds under LRS
Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars.
Search for ProQR Therapeutics and place an order
Find ProQR Therapeutics by name or by its ticker, PRQR, and choose an order type. You can buy by amount or by quantity — fractional shares mean there is no minimum trade size. ProQR Therapeutics trades 7:00 pm – 1:30 am IST; orders can only execute during that window.
Track holdings and download tax reports
Follow your ProQR Therapeutics position in USD and INR. ProQR Therapeutics pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.
Read the full guide: how to invest in ProQR Therapeutics from India
Trading and taxes when buying ProQR Therapeutics from India
Trading and limits
- Trading hours
- 9:30 am – 4:00 pm ET
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- NoneProQR Therapeutics does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained
Custody. Shares are held in your own name at Interactive Brokers LLC and are SIPC-insured up to $500,000 in total, including $250,000 for cash.
FAQs
Can Indian residents buy ProQR Therapeutics stock?
Yes. ProQR Therapeutics (PRQR) has been listed on NASDAQ since 2014, in the Biotechnology industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars. Shares are held in your own name at Interactive Brokers LLC and are SIPC-insured up to $500,000 in total, including $250,000 for cash.
How much does one ProQR Therapeutics share cost in rupees?
One ProQR Therapeutics share is $1.65 — about ₹158 at a USD/INR rate of 95.92 on 25 Sep 2026. Both the ProQR Therapeutics price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for buying ProQR Therapeutics from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.
Can I buy whole shares of ProQR Therapeutics?
Yes. One ProQR Therapeutics share is $1.65, and you can buy as many whole shares as you like. You can also buy by amount rather than by quantity: there is no minimum trade size, and Paasa supports fractional investing in ProQR Therapeutics.
How are gains on ProQR Therapeutics shares taxed in India?
The US does not levy capital gains tax on shares for Indian residents, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the USD/INR rate on the purchase and the sale date, so the rupee move counts alongside the ProQR Therapeutics price. Paasa issues a capital-gains statement for your return.
Does ProQR Therapeutics pay a dividend?
No. ProQR Therapeutics does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.
When can I trade ProQR Therapeutics from India?
NASDAQ trades 7:00 pm – 1:30 am IST in Indian time, so the close lands after midnight. The window shifts to 8:00 pm – 2:30 am IST when the US is on standard time. Orders can only execute during that window.
Is ProQR Therapeutics a United States company, and does that change how it is taxed?
ProQR Therapeutics trades on NASDAQ in US dollars, but the company is domiciled in Netherlands. ProQR Therapeutics trades as an ordinary share listed directly in the US, not a depositary receipt. Some non-US companies list in the US through American Depositary Receipts, which can carry dividend withholding at the company's home-country rate. Your India-side capital-gains treatment is the same either way.
Do I have to declare ProQR Therapeutics shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your ProQR Therapeutics holding, its cost and its closing value.
How do I sell ProQR Therapeutics and bring the money back to India?
You sell during market hours (7:00 pm – 1:30 am IST) and the proceeds settle in USD in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.